Serum MCP-1 (CCL2), MCP-2 (CCL8), RANTES (CCL5), KI67, TNF-β levels in patients with benign and borderline

Objective: The purpose of this study was to assess, among others, monocyte chemoattractant protein type-1 MCP-1 [also called chemokine ligand 2 (CCL2)], MCP-2 (CCL8), regulated on activation, normal T cell expressed and secreted (RANTES) (CCL5), Ki-67, and transforming growth factor beta (TNF-beta) levels in the serum of patients with benign and borderline ovarian lesions. Study Design: Patients who underwent laparoscopy and or laparotomy in the Gynecology and Obstetrics Clinical Hospital, Poznan Medical University, Poland, for adnexal changes in the form of endometrial cysts (n=11) and mature teratomas (n=11), mucinous cysts (n=16), borderline tumors of the ovary (n=17), simplex (serosa) cysts (n=19), or hemorrhagic cysts (n=5) were included in this study. Results: The differences in the medians of MCP-1, MCP-2, RANTES, Ki-67, and TNF-beta were non-statistically significant. Spearman's correlation analysis performed on the group of women with endometriomas showed a statistically significant and positive dependence on the level of RANTES with Ki-67 (r = 0.6; p = 0.0467). Moreover, Spearman's correlation analysis performed on the group of women treated surgically for mature teratomas was statistically significant for the level of MCP-1 with TNF-beta (r = 0.7; p = 0.0301). Conclusion: The study of serum levels of MCP-1 (CCL2), MCP-2, RANTES (CCL5), Ki-67, and TNF-beta in patients with benign and borderline ovarian tumors revealed correlations between the level of RANTES and Ki-67 and of MCP-1 and TNF-beta, which suggests that chemokines as the markers of benign and borderline ovarian tumors are questionable.